GET THE APP

Dalbavancin: A New Pathway for the Treatment of Acute Bacterial S

Health Economics & Outcome Research: Open Access

ISSN - 2471-268X

Short Communication - (2017) Volume 3, Issue 3

Dalbavancin: A New Pathway for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Portugal

Helena Sofia Antão1*, João Paulo Guimarães1, Filipe Froes2, João Almeida3 and Sara Marques3
1Angelini, Medical Department, Rua João Chagas, 53- P3 1499- 040 C. Quebrada- Dafundo, Portugal, E-mail: sofintao@gmail.com
2Hospital Pulido Valente, Centro Hospitalar, Universitário de Lisboa Norte, Portugal, E-mail: sofintao@gmail.com
3Exigo, Alameda dos Oceanos 61, escritório 1.2 Lisboa, 1990-201, Portugal, E-mail: sofintao@gmail.com
*Corresponding Author: Helena Sofia Antão, Angelini Medical Department, Rua João Chagas, 53- P3 1499- 040 C. Quebrada- Dafundo, Portugal, Tel: 00351935128023, Fax: 0351214142981 Email:

Abstract

Background: Acute bacterial skin and skin structure infections are frequent in-hospital infections. Vancomycin and linezolid are antibacterial agents commonly used in serious acute bacterial skin and skin structure infections but have been associated to prolonged length of stay. Dalbavancin is a new lipoglycopeptide antibacterial, active against Gram positive pathogens, with a long half-life, allowing for a single infusion of 1500 mg or 1000 mg followed one week later by 500 mg. The aim of this study was to assess the effect of dalbavancin on length of stay and mortality of acute bacterial skin and skin structure infections patients in Portugal.
Methods and findings: we have modelled the natural history and treatment implications of acute bacterial skin and skin structure infections using a decision analytical tree that calculated the probability of success, failure or death for dalbavancin and linezolid. Efficacy endpoints were obtained from a randomized controlled trial. LOS and mortality due to acute bacterial skin and skin structure infections were derived from non-experimental studies.
Conclusion: we estimated the average length of stay for dalbavancin in 10.4 days. Compared to linezolid this represents a 9.4 day reduction. Dalbavancin is estimated to decrease the death rate by 1.7% in serious acute bacterial skin and skin structure infections caused by Gram positive pathogens and by 1.8% in acute bacterial skin and skin structure infections caused by methicillin-resistant Staphylococus aureus.

Keywords: Acute bacterial skin; Skin structure infections; Methicillin-resistant Staphylococcus aureus; Dalbavancin; Linezolid

Abbreviations

ABSSSI: Acute Bacterial Skin and Skin Structure Infections; LOS: Length of Stay; MRSA: Methicillin-resistant Staphylococcus aureus.

Introduction

Acute bacterial skin and skin structure infections (ABSSSI) are the 4th most frequent cause of in hospital infections in Portugal, accounting for 10.1% of all cases; Staphylococcus aureus and streptococci species are the most prevalent causing agents [1,2]. In Portugal, methicillin-resistant Staphylococcus aureus (MRSA) represents 46.8% of all Staphylococcus aureus species isolates [2]. Retrospective observational data from 12 European countries identified an average length of stay (LOS) in Portuguese hospitals of 25 days for ABSSSI patients, with vancomycin and linezolid as the most used antibacterial agents [3]. Current antibacterial agents used for ABSSSI have limitations concerning safety [4,5] development of resistant strains [6] and patients’ suboptimal adherence to complex regimens [7-9]. ABSSSI are therefore considered a major driver for resource utilization in Portuguese hospitals. Dalbavancin is a new lipoglycopeptide antibacterial agent that is active against Gram positive pathogens. Its extended half-life (8.5 days) and safety profile allow a simplified regimen (either a single infusion of 1500 mg or 1000 mg followed one week later by 500 mg), enhanced compliance and, potentially, early discharges. In selected cases, dalbavancin may be administered in an outpatient setting, which may be of additional benefit when compared to antibacterial agents requiring daily inpatient administration [10,11].

In randomized controlled clinical trials, dalbavancin was noninferior to linezolid with eradication proportions of Gram positive pathogens of 89.5% vs. 87.5%. In the sub-population of ABSSSI caused by MRSA the eradication proportions were 91% and 89% for dalbavancin and linezolid respectively [12]. The objective of this study was to assess the impact of dalbavancin in LOS and mortality due to ABSSSI in Portugal.

Material and Methods

We have modelled the natural history of ABSSSI and its treatment implications using a decision analytical tree. Decision analytical trees are largely used in health and medicine modelling as a method of supporting analysis and decision making [13,14]. Our tree had an initial node related to first line treatment option with three mutually exclusive possible outcomes: success, failure or death. In case of first line treatment failure, patients started a second line treatment. Because of the high cure rates observed in clinical trials and incorporated within the model, the probability of therapy failure in the second line of treatment would be marginal (less than 1%). Therefore, the node for second line treatment considered only success or death as outcomes (Figure 1), i.e., no third line treatments have been considered.

health-economics-outcome-research-Decision-tree-model

Figure 1: Decision tree model adopted for Acute Bacterial Skin and Skin Structure Infections.

Assumptions

The model was based on the following assumptions: (I) linezolid as comparator for dalbavancin as first line treatment and vancomycin as second line treatment for both; this choice was made based on linezolid superiority against vancomycin in clinical outcomes, skin complications and length of hospital stay, as reported by systematic reviews [15]; (II) efficacy endpoint, defined as microbiological efficacy, 14 days after treatment completion, as reported in the randomized clinical trial [12]; (III) safety endpoints, defined as the occurrence of any adverse event with a ≥ 3% frequency for both arms, as reported in randomized clinical trials [12,16]; (IV) assessment of results in the overall population with a baseline Gram positive pathogen and a separate analysis for the population infected with MRSA; the eradication of Gram positive pathogen 14 days after treatment completion results was used as probability of success, based on the treatment duration recommended in current guidelines [17]; (V) due to the acute nature of the disease and high cure rates, second line therapy patients have only two possible outcomes: success or death; (VI) time horizon comprehending the in-hospital stay and the outpatient care periods, including second-line therapy.

ABSSSI probability of death was calculated at 3.8%, the weighted average of ABSSSI in-patients hospital death retrieved from nonexperimental studies [18-21].

We have calculated failure to first line therapy applying the reported microbiological failure rates [12] (dalbavancin: 1-0.89 in the overall population and 1-0.91 in the MRSA population; linezolid: 1-0.875 in the overall population and 1-0.89 in the MRSA population) to the survival probability (inserted in the model as [1 - probability of death, Pdeath]).

In order to identify the percent reduction obtained in mortality (%RM) with dalbavancin versus linezolid for the population with a Gram positive pathogen, the following formula was used:

% RM(a) = 1 − [Pdeath (first line) + Pdeath after drug failure]/ [Pdeath (first line) + Pdeath after comparator failure]

The same rationale was used for the MRSA population; in this case the proportion of patients with MRSA in the population with a Gram positive pathogen (51.17%) was also incorporated

% RM(b) = 1 – ( PMRSA (Gram +) x [Pdeath (first line) + Pdeath after drug failure] / PMRSA (Gram + ) x [Pdeath (first line) + Pdeath after comparator failure]

Since dalbavancin is a recent antibacterial agent, there are no published reports concerning its real world LOS in ABSSSI patients. The ratio between linezolid’s 19.8 days LOS and its 15.2 days duration of treatment (Angelini/Vicuron data on file-VER001-9 Clinical Study report 2014] is, approximately, 1.3. To compare the LOS associated to the two antibacterial agents the same ratio was applied as a correction factor to dalbavancin duration of treatmentassumed, in the model, as the total number of days from the first to the second infusion (8 days). The model was computed using Microsoft Excel 2013 software.

Results

Dalbavancin is estimated to additionally decrease the in-hospital death rate by 1.7% (standard deviation (SD): 2.7%) in the population with an identified Gram positive pathogen and by 1.8% (SD: 3.9%) in MRSA infected sub-population when compared to linezolid (Figure 2).

health-economics-outcome-research-death-rate-achieved

Figure 2: Estimated decrease in death rate achieved with dalbavancin versus linezolid as first line treatment (and vancomycin as second line treatment for both cases) in the populations with ABSSSI due to a Gram positive pathogen and MRSA.

The average LOS with dalbavancin was estimated to be 10.4 days [22]. Compared to the average LOS (19.8 days) for linezolid, this represents an average reduction of 9.4 days in the hospital LOS for ABSSSI patients (Figure 3).

health-economics-outcome-research-Average-length-stay

Figure 3: Average length of stay estimated for the treatment of ABSSSI with dalbavancin or linezolid as first line (and vancomycin as second line treatment in both cases).

Discussion

Treatment of ABSSSI with dalbavancin is estimated to reduce LOS in 9.4 days (47%) versus linezolid, which is one of the current goldstandard antibacterial agents in use for the treatment of these infections. In-hospital death rate is expected to be reduced with dalbavancin by 1.7% and 1.8%, in the population infected by a Gram positive pathogen and by MRSA, respectively, when compared to linezolid. MRSA infected patients are estimated to benefit from a higher impact in inhospital death rate when compared to the population infected by a Gram positive pathogen, which is a relevant potential outcome.

These results reflect the therapeutic value of dalbavancin in the treatment of ABSSSI, which is mainly driven by its convenient administration schedule and high efficacy in MRSA infected population [12]. The current model was the first to estimate LOS and in-hospital mortality in ABSSSI, in Portugal.

Some limitations have to be considered when interpreting these findings, particularly due to the characteristics of the developed model; as with any model, they should be validated in a real-world context.

The model did not incorporate a separate analysis for vancomycin intermediate resistant Staphylococcus aureus (VISA) patients where dalbavacin’s efficacy is expected to be higher. Patients’ adherence was not incorporated in the model. As dalbavancin is an IV regimen with two or one single administration, therapy adherence is expected to be superior to a twice daily regimen such as linezolid’s, which could contribute to more favorable outcomes for dalbavancin.

This model does not capture the potential health risks associated with a prolonged LOS that can additionally affect the burden of ABSSSI. In fact, the benefits of achieving reductions in LOS go far beyond financial savings. The longer the patient stays in a hospital setting the higher the probability of hazardous in-hospital occurrences, such as hospital acquired infections [23]. LOS has also been identified as a mediator of hospital-acquired MRSA [24]. As the European Medicines Agency currently identifies the development of drug resistance as one of the risks of antibacterial agents usage to be addressed through risk management plans [25], the choice of antibacterial agents could potentially be optimized when the associated LOS is taken into account [17]. Reductions in hospitalization length are officially recommended in guidelines concerning the management of ABSSSI [17]. An early discharge may represent additional emotional gains to patients (e.g., relatives proximity, privacy, familiar environment); outpatient parenteral antibacterial therapy programs, when possible, have been associated to high levels of patient satisfaction [26]. We have not included these aspects in our analysis.

These unexploited areas could add to the benefits described above and are suggested to be the object of future research in the field of ABSSSI antibacterial treatment.

Conclusion

Dalbavancin is an effective new approach to provide intravenous antibiotic therapy for patients with ABSSSI, with a favorable safety profile and a simplified dose regimen. Its use as an in-hospital first line intravenous antibiotic therapy to treat severe ABSSSI has the potential to decrease LOS and ABSSSI-associated mortality when compared to first line use of linezolid.

Competing and Conflicting Interests

Helena Sofia Antão and João Paulo Guimarães work in the medical department of Angelini. João Almeida and Susana Marques work for Exigo, a scientific consulting company contracted for the execution of the model.

References

  1. Pina E, Silva G, Ferreira E. Relatório Inquérito de Prevalência de Infecção (2010) Programa Nacional de Prevenção e Controlo de Infecção Associada aos Cuidados de Saúde.
  2. Garau, J, Ostermann H, Medina J (2013) Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010–2011): Assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study. Clin Microbiol Infect 19: E377-E385.
  3. Eckmann C, Lawson W, Nathwani, D (2014) Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to meticillin-resistant Staphylococcus aureus: a plea for implementation of early switch and early discharge criteria. Int J Antimicrob Agents 44: 56-64.
  4. Zhang X, Falagas ME, Vardakas KZ (2015) Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. J Thorac Dis 7: 603.
  5. Tongsai S, Koomanachai P (2016) The safety and efficacy of high versus low vancomycin trough levels in the treatment of patients with infections caused by methicillin-resistant Staphylococcus aureus: a meta-analysis. BMC Res Notes 9: 455.
  6. D’Agata EM, Magal P, Olivier D (2007) Modeling antibiotic resistance in hospitals: the impact of minimizing treatment duration. J Theor Biol 249: 487-499.
  7. Cals JW, Hopstaken RM, Le Doux PH (2008) Dose timing and patient compliance with two antibiotic treatment regimens for lower respiratory tract infections in primary care. Int J Antimicrob Agents 31: 531-536.
  8. Kardas P (2007) Comparison of patient compliance with once-daily and twice-daily antibiotic regimens in respiratory tract infections: results of a randomized trial. J Antimicrob Chemother 59: 531-536.
  9. Ball AT, Xu Y, Sanchez RJ (2010) Nonadherence to oral linezolid after hospitalization: a retrospective claims analysis of the incidence and consequence of claim reversals. Clin Ther 32: 2246-2255.
  10. Stevens DL, Bisno AL, Chambers HF (2015) Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 41: 1373-1406.
  11. Seltzer E, Dorr MB, Goldstein BP, Perry M (2003) Dalbavancin Skin and Soft-Tissue Infection Study Group. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 37: 1298-1303.
  12. Jauregui LE, Babazadeh S, Seltzer E (2005) Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 41: 1407-1415.
  13. Rudmik L, Drummond M. (2013) Health economic evaluation: important principles and methodology. Laryngoscope 123: 1341-1347.
  14. Hunink MGM, Weinstein MC, Wittenberg E (2014)Decision Making in Health and Medicine: Integrating Evidence and Values. 2nd ed. Spain: Cambridge University Press.
  15. Yue J, Dong BR, Yang M (2016) Linezolid versus vancomycin for skin and soft tissue infections. Cochrane Database Syst Rev 1: Cd008056.
  16. Weigelt J, Itani K, Stevens D (2005) Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 49: 2260-2266.
  17. Stevens DL, Bisno AL, Chambers HF (2014) Practice guidelines for the diagnosis and anagement of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 59: e10-e52.
  18. Lipsky BA, Moran GJ, Napolitano LM (2012) A prospective, multicenter, observational study of complicated skin and soft tissue infections in hospitalized patients: clinical haracteristics, medical treatment, and outcomes. BMC Infect Dis 12: 227.
  19. Itani KM, Merchant S, Lin SJ (2011) Outcomes and management costs in patients hospitalized for skin and skin-structure infections. Am J Infect Control 39: 42-49.
  20. Lipsky BA, Tabak YP, Johannes RS (2010) Skin and soft tissue infections in hospitalized patients with diabetes: culture isolates and risk factors associated with mortality, length of stay and cost. Diabetologia 53: 914-923.
  21. Zilberberg MD, Shorr AF, Micek ST (2009) Epidemiology and outcomes of hospitalizations with complicated skin and skin-structure infections: implications of healthcare- associated infection risk factors. Infect Control Hosp Epidemiol 30: 1203-1210.
  22. Li JZ, Willke RJ, Rittenhouse BE (2003) Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial. Surg Infect 4: 57-70.
  23. Jeon CY, Neidell M, Jia H, Sinisi M (2012) On the role of length of stay in healthcare-associated bloodstream infection. Infect Control Hosp Epidemiol 33: 1213-1218.
  24. Wong JG, Chen MI, Win MK (2016) Length of stay an important mediator of hospital-acquired methicillin-resistant Staphylococcus aureus. Epidemiol Infect 144: 1248-1256.
  25. European Medicines Agency (2016) Antibacterial resistance in human medicine
  26. Muldoon EG, Snydman DR, Penland EC (2013) Are we ready for an outpatient parenteral antimicrobial therapy bundle? A critical appraisal of the evidence. Clin Infect Dis 57: 419-424.
Citation: Antão HS, Guimarães JP, Froes F, Almeida J, Marques S (2017) Dalbavancin: A New Pathway for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Portugal. Health Econ Outcome Res Open Access 3: 138.

Copyright: © 2017 Antão HS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.